Si quieres leer este artículo en Español, por favor clica aquí.
Huge congratulations are in order for Bionure, a biotech company developing a novel first-in-class drug for the treatment of multiple sclerosis, who are currently overfunding on the Capital Cell crowdfunding platform.
With more than €1M raised, this campaign is breaking records by becoming the largest amount raised on a life science equity crowdfunding platform to date, in Spain. Valued at 9,400,000€ and with an estimated ROI of 1400%, Bionure is now at 110% of its funding goal and keeps on rising.
The capital raised from over 240 investors sharing 9.27% equity in the business will be used by the company to develop BN201, a promising first-in-class drug candidate halt the development of multiple sclerosis. This disease affects about 2.5 million people worldwide and more than 600,000 in Europe. To date there is no cure.
Multiple sclerosis is a neurodegenerative disease in which the immune system destroys the nervous system, degrading the myelin layer that covers and protects the nerves. This new drug acts as a neuroprotector, preventing the nervous system from damage and reversing the detrimental effects. At present, there is no other drug with this dual role of neuroprotection and regeneration, making BN201 a unique product and a hope to multiple sclerosis patients, but also other neurodegenerative diseases such as Parkinson and Alzheimer.
After more than six years of research, this late-preclinical drug development company based in Barcelona and California will now be able to take the next big and imperative step: to complete their preclinical phase and begin the BN201 promising phase-I clinical trials. They will test its effectiveness in patients with Acute Optic Neuritis (AON), a condition known to be one of the first signs of multiple sclerosis.
As happens with many of the projects raising funds with Capital Cell, Bionure’s campaign ‘#estamosaesto’ (‘we are this close’) is capturing the interest of an heterogeneous ‘crowd’ of investors. On the one hand, there’s the huge social impact that a drug like BN201 could have. “We have been contacted by multiple sclerosis patients, by their relatives and friends, who see this an exceptional opportunity to help” reveals Daniel Oliver, our CEO. Whilst on the other hand, there’s the impressive business opportunity that Bionure represents: the estimated market for a neuro regenerative drug such as BN201 is about €1.2 billion. “That’s why we are capturing the interest of big investors who see the high social impact but also the high profitability of their investment”, adds Daniel.
“Capital Cell has been a constant support helping to raise awareness of our campaign. The platform is a great way to expand funding possibilities, reaching investors that we would had never been able to reach”, argues Albert G. Zamora, Bionure CEO.
“This is a fantastic representation of Capital Cell as a reputable equity investment platform, in the run up to our UK Launch” says Daniel. Following the success of Capital Cell in its country of origin, Spain, the company is currently in the pre-launch phase of expanding into the UK market. “We’re showcasing some amazing, innovative scientific research projects, and giving smaller companies the opportunity to make big changes in the world of life science. Capital Cell provides investors at all levels with the opportunity to not only directly fund companies that can change lives, but also invest in one of the most profitable sectors around”, adds Laura Ferguson, UK Director.
“This is a fantastic representation of Capital Cell as a reputable equity investment platform, in the run up to our UK Launch” continues Daniel. Following the success of Capital Cell in Spain, the company is currently in the pre-launch phase of expanding into the UK market. “We are showcasing some amazing, innovative scientific research projects, and giving smaller companies the opportunity to make big changes in the world of life science. Capital Cell provides investors at all levels with the opportunity to not only directly fund companies that can change lives, but also invest in one of the most profitable sectors around”, adds Laura Ferguson, UK Director.
Bionure’s success is coming at an important moment for Capital Cell, giving the team extra motivation to embrace this new UK challenge!
The Capital Cell team thanks each one of the 240+ Bionure investors that are helping us make BN201 a reality. Together we are making something special!
And “if you want to help shape the future of Multiple Sclerosis treatment, there’s still time to invest! Invest Now!”, reminds Albert from Bionure.